Bioequivalence study of the oral suspension of netupitant/palonosetron combination product versus the hard capsules of netupitant/palonosetron combination product after a single dose administration to healthy male and female volunteers in an open-label, randomised, single centre, 2-treatment, 4-period, 2 sequence replicative design
NEPA-23-01
Phase 1 other active
Quick answer
Bioequivalence study of the oral suspension of netupitant/palonosetron combination product versus the hard capsules of netupitant/palonosetron combination product after a single dose administration to healthy male and female volunteers in an open-label, randomised, single centre, 2-treatment, 4-period, 2 sequence replicative design for Healthy volunteers is a Phase 1 program (other) at Helsinn Birex Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Helsinn Birex Pharmaceuticals
- Indication
- Healthy volunteers
- Phase
- Phase 1
- Modality
- other
- Status
- active